Hermann Einsele

Lighthouse Guild — United States

Medicine · Health Sciences

136h-index72.9kcitations1.6kworks5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(640), Protein Degradation and Inhibitors(256), CAR-T cell therapy research(240), Hematopoietic Stem Cell Transplantation(171), Antifungal resistance and susceptibility(142)

Publications1.6k total

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis
2025Open Access
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Cancer Cell·2025Open Access
Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Advances in Therapy·2025Open Access
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies
Biomarker Research·2025· 1 citedOpen Access
Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Figure 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Supplementary Table 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
2025Open Access
Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT
Bone Marrow Transplantation·2025
Cardiovascular determinants of the 6-minute walk distance in cardiac transthyretin amyloidosis
BMC Cardiovascular Disorders·2025Open Access
Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells
Blood·2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy
Blood·2025
Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma
Blood·2025Open Access
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
Blood·2025
An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma
Blood·2025Open Access
NQO1 modulates CD38 surface expression in multiple myeloma
Blood·2025
page 1 of 80Next →

Frequent Co-authors

Jesús F. San Miguel(19), Philippe Moreau(18), Meletios Α. Dimopoulos(16), Pieter Sonneveld(16), Michèle Cavo(14), Brian G.M. Durie(13), Sagar Lonial(12), Hartmut Goldschmidt(12), Kenneth C. Anderson(11), Antonio Palumbo(10), María‐Victoria Mateos(10), Paul G. Richardson(10), Roman Hájek(10), Joan Bladé(9), S. Vincent Rajkumar(9), Mario Boccadoro(9), Heinz Ludwig(8), Evangelos Terpos(8), Robert Z. Orlowski(7), Meral Beksaç(6)